AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37351456 — intervention group
Group type: EXPERIMENTAL
Intervention: Adintrevimab (300 mg, single intramuscular injection)
Number of subjects: 399
Study 37351456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 37351464 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-based training sessions
Number of subjects: 18
Study 37351564 — intervention group
Group type: EXPERIMENTAL
Intervention: Orforglipron (12, 24, 36, or 45 mg)
Number of subjects: 272
Study 37351564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 37351585 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (12 weeks acute phase and 16 weeks continuation phase)
Number of subjects: 425
Study 37351639 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of fatigue guidelines
Number of subjects: 144
Study 37351639 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy to intervene for fatigue
Number of subjects: 144
Study 37351639 — intervention group
Group type: EXPERIMENTAL
Intervention: General knowledge about fatigue
Number of subjects: 144
Study 37351639 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of empirical evidence for psychotherapeutic interventions
Number of subjects: 144
Study 37351639 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday physical activity awareness
Number of subjects: 144
Study 37351639 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga awareness
Number of subjects: 144
Study 37351639 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions awareness
Number of subjects: 144
Study 37351639 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of resistance/endurance training
Number of subjects: 144
Study 37351639 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation frequency for resistance/endurance training
Number of subjects: 144
Study 37351640 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral parallel elliptical flap (BPEF)
Number of subjects: 102
Study 37351640 — intervention group
Group type: COMPARATOR
Intervention: Karydakis flap (KF)
Number of subjects: 102
Study 37351709 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use among male couples
Number of subjects: 934
Study 37351781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 371
Study 37351781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 37351798 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway implementation
Number of subjects: 2878
Study 37351885 — intervention group
Group type: EXPERIMENTAL
Intervention: REBECCA intervention (nurse navigation and symptom screening)
Number of subjects: 309
Study 37351885 — intervention group
Group type: EXPERIMENTAL
Intervention: REBECCA intervention
Number of subjects: 309
Study 37351885 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 309
Study 37351932 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI) treatment delivered via telephone for smoking cessation.
Number of subjects: 1200
Study 37351932 — intervention group
Group type: COMPARATOR
Intervention: Standard evidence-based behavioral treatment delivered via telephone.
Number of subjects: 1200
Study 37351941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway Platform (digital tool)
Number of subjects: 0
Study 37351941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway app (earlier iteration)
Number of subjects: 0
Study 37351941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway Platform
Number of subjects: 0
Study 37352120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia
Number of subjects: 100
Study 37352120 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of colloid
Number of subjects: 100
Study 37352144 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic participants (76.2%)
Number of subjects: 759
Study 37352144 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom duration correlated with disease severity
Number of subjects: 759
Study 37352144 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung disease
Number of subjects: 759
Study 37352144 — intervention group
Group type: EXPERIMENTAL
Intervention: Race
Number of subjects: 759
Study 37352144 — intervention group
Group type: EXPERIMENTAL
Intervention: Global region
Number of subjects: 759
Study 37352144 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged viral shedding
Number of subjects: 759
Study 37352211 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of PASC, measured by signs and symptoms.
Number of subjects: 14880
Study 37352211 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly questionnaires about symptoms, social determinants, vaccination status, and interim SARS-CoV-2 infections.
Number of subjects: 14880
Study 37352211 — intervention group
Group type: EXPERIMENTAL
Intervention: Biospecimens and physical/laboratory examinations at approximately 0, 90, and 180 days from infection or negative test date.
Number of subjects: 14880
Study 37352211 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression and proportional hazards regression analysis.
Number of subjects: 14880
Study 37352262 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/methotrexate (full-MTX)
Number of subjects: 96
Study 37352262 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus/reduced-dose methotrexate/mycophenolate (mini-MTX/MMF)
Number of subjects: 96
Study 37352266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg and brentuximab vedotin (BV) 1.8 mg/kg once every 3 weeks until disease progression or unacceptable toxicity.
Number of subjects: 29
Study 37352284 — intervention group
Group type: COMPARATOR
Intervention: Structured Emotionally Focused Family Therapy (EFFT)
Number of subjects: 20
Study 37352322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox 60-day treatment regimen
Number of subjects: 127
Study 37352322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox 30-day treatment regimen
Number of subjects: 127
Study 37352479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene combined with abemaciclib
Number of subjects: 29
Study 37352479 — intervention group
Group type: COMPARATOR
Intervention: Traditional model
Number of subjects: 29
Study 37352479 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-TIME model
Number of subjects: 29
Study 37352498 — intervention group
Group type: EXPERIMENTAL
Intervention: pomalidomide 5 mg orally for 21 days of 28-day cycles for up to 1 year
Number of subjects: 19
Study 37352520 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 49
Study 37352525 — intervention group
Group type: EXPERIMENTAL
Intervention: New procedure: left atrial geometric volume reduction combined with left appendage base closure
Number of subjects: 0
Study 37352525 — intervention group
Group type: COMPARATOR
Intervention: Cox-Maze IV treatment
Number of subjects: 0
Study 37352612 — intervention group
Group type: EXPERIMENTAL
Intervention: BNZ-1
Number of subjects: 0
Study 37352806 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital phenotype profile (DPP) tool
Number of subjects: 0
Study 37352806 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted support vector machine with leave-one-subject-out-cross-validation
Number of subjects: 0
Study 37352806 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models (support vector machine and decision tree)
Number of subjects: 0
Study 37352880 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolised Ad5-nCoV
Number of subjects: 10267
Study 37352880 — intervention group
Group type: COMPARATOR
Intervention: Inactivated vaccine
Number of subjects: 10267
Study 37353155 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of iliac venous outflow obstruction (IVOO) categorized as obstruction <50% (category 1), 50% to 79% (category 2), and ≥80% (category 3)
Number of subjects: 51
Study 37353155 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep venous reflux (DVR)
Number of subjects: 51
Study 37353155 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous deep vein thrombosis (DVT)
Number of subjects: 51
Study 37353155 — intervention group
Group type: EXPERIMENTAL
Intervention: Left limb involvement
Number of subjects: 51
Study 37353155 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous clinical severity score (VCSS)
Number of subjects: 51
Study 37353155 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflux multisegment score (RMS)
Number of subjects: 51
Study 37353155 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear association between the degree of IVOO and reflux
Number of subjects: 51
Study 37353154 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT)
Number of subjects: 72
Study 37353154 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone (ACA)
Number of subjects: 72
Study 37353270 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T cells
Number of subjects: 0
Study 37353270 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 37353277 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue disease-modifying therapy
Number of subjects: 259
Study 37353277 — intervention group
Group type: COMPARATOR
Intervention: Discontinue disease-modifying therapy
Number of subjects: 259
Study 37353278 — intervention group
Group type: EXPERIMENTAL
Intervention: Descartes-08 (autologous anti-BCMA rCAR-T therapy)
Number of subjects: 14
Study 37353342 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced diagnostic workup
Number of subjects: 356
Study 37353342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular MR imaging (CMR)
Number of subjects: 356
Study 37353342 — intervention group
Group type: EXPERIMENTAL
Intervention: Study-related ECG monitoring
Number of subjects: 356
Study 37353342 — intervention group
Group type: COMPARATOR
Intervention: Routine monitoring
Number of subjects: 356
Study 37353450 — intervention group
Group type: EXPERIMENTAL
Intervention: HepB-CpG vaccine
Number of subjects: 10
Study 37353495 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI) treatment
Number of subjects: 48
Study 37353645 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Parenting for Anxious Childhood Emotions (SPACE)
Number of subjects: 15
Study 37353654 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vacuum therapy (EVT)
Number of subjects: 44
Study 37353654 — intervention group
Group type: COMPARATOR
Intervention: Self-expandable metal stent (SEMS)
Number of subjects: 44
Study 37353654 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment timing
Number of subjects: 44
Study 37353654 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of procedures per patient
Number of subjects: 44
Study 37353654 — intervention group
Group type: COMPARATOR
Intervention: SEMS complications
Number of subjects: 44
Study 37353726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger measured on a 0-10 numeric rating scale
Number of subjects: 515
Study 37353726 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirst measured on a 0-10 numeric rating scale
Number of subjects: 515
Study 37353726 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral grades and numeric rating scale for thirst
Number of subjects: 515
Study 37353726 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral grades and numeric rating scale for hunger
Number of subjects: 515
Study 37353788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 437
Study 37353788 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour necrosis factor inhibitor (TNFi)
Number of subjects: 437
Study 37353795 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely delivered TEACH program plus treatment as usual (TAU)
Number of subjects: 0
Study 37353795 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 0
Study 37353798 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition-based non-financial incentives package (certificates and government-branded jackets awarded in a public ceremony)
Number of subjects: 240
Study 37353798 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition-based non-financial incentives package
Number of subjects: 240
Study 37353809 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 173
Study 37353809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 37353855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative physiological stress load
Number of subjects: 66
Study 37353855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative physiological stress load components (DHEA-S, urinary norepinephrine)
Number of subjects: 66
Study 37353855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative physiological stress load components (waist circumference, blood pressure, CRP, HbA1c)
Number of subjects: 66
Study 37354000 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomere Shortest Length Assay (TeSLA)
Number of subjects: 18
Study 37354000 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=22)
Number of subjects: 18
Study 37354048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir 300 mg/100 mg
Number of subjects: 36
Study 37354048 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir 100 mg
Number of subjects: 36
Study 37354048 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg
Number of subjects: 36
Study 37354048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 75 mg
Number of subjects: 36
Study 37354069 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorasidenib
Number of subjects: 0
Study 37354069 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37354146 — intervention group
Group type: EXPERIMENTAL
Intervention: PADN
Number of subjects: 98
Study 37354146 — intervention group
Group type: COMPARATOR
Intervention: sham + sildenafil
Number of subjects: 98
Study 37354201 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Intelligence Training (SIT)
Number of subjects: 349
Study 37354201 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Condition (ACC)
Number of subjects: 349
Study 37354245 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle change intervention for six months
Number of subjects: 0
Study 37354245 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 37354260 — intervention group
Group type: EXPERIMENTAL
Intervention: Optilume BPH Catheter System
Number of subjects: 80
Study 37354276 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (DMF)
Number of subjects: 5251
Study 37354546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid, 180 mg daily (n=2100)
Number of subjects: 13970
Study 37354546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid (n=2100)
Number of subjects: 13970
Study 37354546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=2106)
Number of subjects: 13970
Study 37354554 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of daily low-dose hCG (260 IU recombinant hCG) administration before IVF/ICSI cycle
Number of subjects: 20
Study 37354554 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (no hCG priming)
Number of subjects: 20
Study 37354562 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec
Number of subjects: 588
Study 37354562 — intervention group
Group type: COMPARATOR
Intervention: Once-daily insulin degludec
Number of subjects: 588
Study 37354762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraprocessed food (UPF) consumption
Number of subjects: 305
Study 37354778 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum chromium everolimus-eluting stent implantation
Number of subjects: 4175
Study 37354947 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Bridge Program
Number of subjects: 60
Study 37354976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactase persistence (LP) genotype individuals
Number of subjects: 279
Study 37354976 — intervention group
Group type: COMPARATOR
Intervention: Lactase nonpersistent (LNP) individuals consuming more than 12.46 g/d
Number of subjects: 279
Study 37354976 — intervention group
Group type: COMPARATOR
Intervention: LNP individuals consuming the upper tercile of lactose
Number of subjects: 279
Study 37354976 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated lactose consumption in individuals with the LNP genotype
Number of subjects: 279
Study 37354978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive arm
Number of subjects: 1678
Study 37354978 — intervention group
Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 1678
Study 37355035 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-assisted intervention (12-week program including 3 center-based supervised exercise sessions, a fitness watch, 6 educational videos, and weekly video calls)
Number of subjects: 28
Study 37355035 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-assisted intervention
Number of subjects: 28
Study 37355035 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 28
Study 37355043 — intervention group
Group type: EXPERIMENTAL
Intervention: efinopegdutide 10 mg weekly
Number of subjects: 145
Study 37355043 — intervention group
Group type: COMPARATOR
Intervention: semaglutide 1 mg weekly
Number of subjects: 145
Study 37355044 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression with instrumented fusion
Number of subjects: 267
Study 37355044 — intervention group
Group type: COMPARATOR
Intervention: Decompression alone
Number of subjects: 267
Study 37355044 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 267
Study 37355155 — intervention group
Group type: EXPERIMENTAL
Intervention: AWARE (Motivational Interviewing-based group intervention)
Number of subjects: 276
Study 37355155 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 276
Study 37355263 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal occupational therapy including patient education, hand exercises, assistive devices and orthoses (n=90)
Number of subjects: 180
Study 37355263 — intervention group
Group type: COMPARATOR
Intervention: Usual care receiving only information on OA (n=90)
Number of subjects: 180
Study 37355267 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) - four cycles of cuff inflation for 5 min to 200 mm Hg and deflation for 5 min.
Number of subjects: 766
Study 37355267 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 766
Study 37355267 — intervention group
Group type: COMPARATOR
Intervention: Control treatment - identical-looking cuff placed around the arm but not inflated.
Number of subjects: 766
Study 37355270 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of in-bed cycling in addition to routine physiotherapy (PT), 5 days per week, up to 28 days maximum
Number of subjects: 360
Study 37355270 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy (PT) alone
Number of subjects: 360
Study 37355275 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic evaluation of staging and activity of invasive fungal infection (IFI)
Number of subjects: 0
Study 37355275 — intervention group
Group type: COMPARATOR
Intervention: Anatomy-based imaging
Number of subjects: 0
Study 37355274 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum depression screening by family paediatricians using Whooley questions during visits at 60-90 days and 5-7 months after childbirth.
Number of subjects: 2203
Study 37355274 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal postnatal depressive symptoms
Number of subjects: 2203
Study 37355274 — intervention group
Group type: EXPERIMENTAL
Intervention: Child sleeping disorders at 3 months
Number of subjects: 2203
Study 37355274 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a likely depressed partner
Number of subjects: 2203
Study 37355412 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil alone
Number of subjects: 2
Study 37355412 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 2
Study 37355412 — intervention group
Group type: COMPARATOR
Intervention: Combination of remifentanil and propofol
Number of subjects: 2
Study 37355418 — intervention group
Group type: EXPERIMENTAL
Intervention: Melflufen plus dexamethasone
Number of subjects: 495
Study 37355418 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide
Number of subjects: 495
Study 37355476 — intervention group
Group type: EXPERIMENTAL
Intervention: High PAHCO profile (46% of patients)
Number of subjects: 98
Study 37355476 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate PAHCO profile (48% of patients)
Number of subjects: 98
Study 37355476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PAHCO profile (5% of patients)
Number of subjects: 98
Study 37355476 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile one (32% of patients)
Number of subjects: 98
Study 37355476 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile two (40% of patients)
Number of subjects: 98
Study 37355476 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile three (15% of patients)
Number of subjects: 98
Study 37355476 — intervention group
Group type: EXPERIMENTAL
Intervention: High PAHCO profile
Number of subjects: 98
Study 37355526 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (NST)
Number of subjects: 500
Study 37355565 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation during endoscopy
Number of subjects: 30
Study 37355583 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol deviations reported during the trial
Number of subjects: 5407
Study 37355583 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive actions taken in response to protocol deviations
Number of subjects: 5407
Study 37355622 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Pain to Enhance Living Well intervention (including video modules, activity trackers, and nurse consultations)
Number of subjects: 40
Study 37355622 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Pain to Enhance Living Well intervention
Number of subjects: 40